You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Desvenlafaxine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00256685 ↗ Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2004-09-01 The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
NCT00277823 ↗ Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-02-01 The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
NCT00283842 ↗ Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy Terminated Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-03-01 The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NCT00300378 ↗ Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-03-01 The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Desvenlafaxine

Condition Name

Condition Name for Desvenlafaxine
Intervention Trials
Major Depressive Disorder 27
Depressive Disorder, Major 9
Depression 8
Vasomotor Symptoms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Desvenlafaxine
Intervention Trials
Depression 46
Depressive Disorder 45
Depressive Disorder, Major 42
Disease 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Desvenlafaxine

Trials by Country

Trials by Country for Desvenlafaxine
Location Trials
United States 499
Canada 31
Japan 21
Mexico 9
South Africa 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Desvenlafaxine
Location Trials
Florida 26
Ohio 23
California 22
Texas 20
Georgia 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Desvenlafaxine

Clinical Trial Phase

Clinical Trial Phase for Desvenlafaxine
Clinical Trial Phase Trials
Phase 4 17
Phase 3 30
Phase 2/Phase 3 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Desvenlafaxine
Clinical Trial Phase Trials
Completed 55
Terminated 6
Unknown status 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Desvenlafaxine

Sponsor Name

Sponsor Name for Desvenlafaxine
Sponsor Trials
Pfizer 27
Wyeth is now a wholly owned subsidiary of Pfizer 25
Luye Pharma Group Ltd. 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Desvenlafaxine
Sponsor Trials
Industry 61
Other 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Desvenlafaxine: Clinical Trials, Market Analysis, and Projections

Introduction to Desvenlafaxine

Desvenlafaxine, marketed under the brand name Pristiq, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of major depressive disorder (MDD). Here, we will delve into the recent clinical trials, market analysis, and future projections for this medication.

Clinical Trials Update

Pediatric Study

In a significant clinical trial, Pfizer evaluated the efficacy, safety, and tolerability of desvenlafaxine succinate sustained-release formulation in pediatric patients with MDD. This Phase 3 study, conducted under the Pediatric Research Equity Act (PREA), involved 340 subjects aged 7 to 17. The study did not meet its primary objective of demonstrating superior efficacy of desvenlafaxine succinate compared to placebo. Both desvenlafaxine and the positive control, fluoxetine, were not statistically significantly different from placebo in terms of efficacy. However, no new safety signals were identified, and adverse events were consistent with previous studies[1].

Adult Studies

In adult populations, desvenlafaxine has shown promising results. Four 8-week, randomized, double-blind, placebo-controlled studies established the efficacy of desvenlafaxine in treating MDD. Additionally, longer-term trials (Studies 5 and 6) demonstrated that patients receiving continued desvenlafaxine treatment experienced a statistically significant longer time to relapse compared to those on placebo. These studies highlighted the effectiveness of desvenlafaxine in maintaining remission and preventing relapse in patients with MDD[4].

Market Analysis

Current Market Size

The global desvenlafaxine succinate market was valued at USD 100 billion in 2023. This market is segmented by type (tablets, extended-release tablets, capsules, injectables) and application (MDD treatment, anxiety disorder treatment, fibromyalgia management, neuropathic pain management, menopausal symptom relief)[3].

Key Manufacturers

The market is dominated by key manufacturers such as Teva API and Allastir Private. These companies play a crucial role in the production and distribution of desvenlafaxine succinate, contributing significantly to the market share and revenue[2].

Regional Market

The market is geographically divided into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Each region is expected to grow at a different CAGR, with North America and Europe being significant contributors due to high healthcare spending and increased awareness of mental health[2][3].

Market Projections

Growth Rate

The desvenlafaxine succinate market is projected to grow at a Compound Annual Growth Rate (CAGR) of 5% from 2024 to 2031, reaching an estimated value of USD 140.71 billion by 2031. This growth is driven by several factors, including the increasing prevalence of anxiety and depression, advancements in pharmaceutical R&D, and expanding access to mental health services[3].

Driving Factors

Several factors are driving the growth of the desvenlafaxine succinate market:

  • Increasing Prevalence of Mental Health Disorders: The rising awareness and incidence of mental health issues globally are driving the demand for effective treatments like desvenlafaxine.
  • Pharmaceutical Innovations: Continuous innovations in formulations and the exploration of new indications are expanding the market potential.
  • Aging Population and Stressful Lifestyles: An aging population and increasingly stressful lifestyles contribute to the growing need for mental health treatments[3].

Competitive Landscape

The market is competitive, with pharmaceutical companies focusing on creating new formulations and increasing product availability in growing regions. The effectiveness of desvenlafaxine succinate in targeting both serotonin and norepinephrine, along with its extended-release formulation, makes it an attractive option for healthcare professionals seeking comprehensive treatment options for depression[3].

Future Outlook

Expanding Indications

Current clinical studies are investigating new indications for desvenlafaxine succinate, including anxiety disorders. This expansion is expected to further drive market growth as the drug becomes more versatile in its applications[3].

Global Access

The global desvenlafaxine succinate market is expected to benefit from increasing access to mental health services and rising healthcare costs. As more regions invest in mental health care, the demand for desvenlafaxine succinate is likely to increase[3].

Key Takeaways

  • Clinical Trials: Recent pediatric trials did not meet primary objectives, but adult studies have shown significant efficacy in treating MDD and preventing relapse.
  • Market Size: The global market was valued at USD 100 billion in 2023 and is projected to reach USD 140.71 billion by 2031.
  • Growth Rate: The market is expected to grow at a CAGR of 5% from 2024 to 2031.
  • Driving Factors: Increasing prevalence of mental health disorders, pharmaceutical innovations, and expanding access to mental health services are key drivers.
  • Competitive Landscape: The market is competitive, with a focus on new formulations and expanding product availability.

FAQs

Q: What is the primary use of desvenlafaxine succinate?

A: Desvenlafaxine succinate is primarily used for the treatment of major depressive disorder (MDD).

Q: What were the results of the pediatric clinical trial for desvenlafaxine succinate?

A: The pediatric clinical trial did not meet its primary objective of demonstrating superior efficacy of desvenlafaxine succinate compared to placebo.

Q: Which companies are key manufacturers of desvenlafaxine succinate?

A: Key manufacturers include Teva API and Allastir Private.

Q: What is the projected growth rate of the desvenlafaxine succinate market?

A: The market is projected to grow at a CAGR of 5% from 2024 to 2031.

Q: What factors are driving the growth of the desvenlafaxine succinate market?

A: The growth is driven by the increasing prevalence of mental health disorders, pharmaceutical innovations, and expanding access to mental health services.

Sources

  1. Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder. Pfizer Inc.
  2. Global Desvenlafaxine Succinate Market Insights, Forecast to 2030. QY Research.
  3. Desvenlafaxine Succinate Market Size and Projections. Market Research Intellect.
  4. PRISTIQ® (desvenlafaxine succinate) Clinical Studies - US. Pfizer Medical Information.
  5. Desvenlafaxine Market Report 2024 (Global Edition). Cognitive Market Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.